UCB SA (UNC.F)
| Previous close | 122.65 |
| Open | 121.00 |
| Bid | 123.55 x 30700 |
| Ask | 126.00 x 30700 |
| Day's range | 121.00 - 121.00 |
| 52-week range | 65.68 - 125.00 |
| Volume | |
| Avg. volume | 97 |
| Market cap | 22.963B |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | 69.14 |
| EPS (TTM) | 1.75 |
| Earnings date | 24 Jul 2024 - 03 Aug 2024 |
| Forward dividend & yield | 1.36 (1.11%) |
| Ex-dividend date | 26 Apr 2024 |
| 1y target est | N/A |
GuruFocus.comUCB SA's Dividend Analysis
UCB SA (UCBJY) recently announced a dividend of $0.73 per share, payable on 2024-05-15, with the ex-dividend date set for 2024-04-26. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into UCB SA's dividend performance and assess its sustainability.
PR NewswireUCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the latest research from its expansive neurology portfolio and pipeline to be presented at the 76th American Academy of Neurology (AAN) Annual Meeting, April 13-18, 2024, in Denver, Colorado, USA.
PR NewswireUCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa
UCB, a global biopharmaceutical company, today announced the launch of Make HStory, an educational campaign that provides tools and resources for those living with hidradenitis suppurativa (HS) and their dermatologists.
